Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, announced the agency's approval of COVID boosters for 6-month-olds, citing a trial with just 24 patients.
The U.S. Food & Drug Administration (FDA) is approving booster doses of Pfizer’s COVID-19 shot for children as young as six months based on a trial of just 24 patients.
The FDA announced March 14 that it is amending its emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine, Bivalent, to allow a single booster dose for children between six months and four years, at least two months after being initially vaccinated.
“Currently available data show that vaccination remains the best defense against severe disease, hospitalization and death caused by COVID-19 across all age groups, and we encourage all eligible individuals to make sure that their vaccinations are up to date with a bivalent COVID-19 vaccine,” claimed Dr. Peter Marks, director of the FDA’s Cente...